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Sterile filtration is widely used among manufacturers to sterilize vaccine antigens, utilizing 0.2 µm nominal pore
size membranes to remove all bacteria. Incorporation of a sterile filtration step significantly reduces
manufacturing burden by eliminating the need for a fully aseptic end-to-end manufacturing process. Although
the sterile filtration of recombinant proteins is relatively straightforward, live attenuated viral (LAV) vaccines with
large particle sizes (100 – 400 nm) pose significant challenges during sterile filtration, specifically low yields and
capacities. Experimental studies were performed with both an LAV and a model particle system. Small
differences in the average pore size of sterile filters (determined by mercury porosimetry) had a large effect on
the particle transmission, with the Sartobran P (average pore size of 0.46 µm) having more than 80% viral
particle yield while the Millipore Express SHF (average pore size of 0.33 µm) had a particle yield of <1%. In
addition, the filter capacity and particle yield could be significantly increased using appropriate prefilters due to
selective removal of larger particles in the feed suspension. Confocal and scanning electron microscopy were
used to directly evaluate the extent and location of foulant capture within both the prefilter and sterile filters. This
work provides important insights into the factors controlling sterile filtration of large particle vaccines and
enables sterile filtration of vaccine products previously assumed to be too large for sterile filtration. The work
also provides a framework for enhancing the yield and capacity of commercially available sterile filters.
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